| Name | Title | Contact Details |
|---|---|---|
Daniel Schwalbe |
Chief Information Security Officer and Vice President of Information Technology | Profile |
Sean McNee |
Chief Technology Officer | Profile |
James Reynolds |
Chief Technology Officer | Profile |
CommandLink is a company that builds software defined network and communication infrastructure as a service. They offer Next Generation Software Defined Hybrid Networks (SD WAN) with integrated managed security, unified with Cloud Communications and Co...
Adarma is a UK-based cybersecurity services company that provides consulting, technology, and managed security services to protect organizations against an increasingly complex and harmful threat landscape.
Cisive is a leading global background screening provider focused on providing high-value employment background checks and industry-specific compliance services to highly regulated, risk-sensitive industries. Cisive has long-term relationships with a diverse base of clients across healthcare, financial services, transportation and other regulated industries. Founded in 1977, Cisive has developed a broad range of differentiated vertical business lines and risk mitigation offerings including the core Cisive brand (global and enterprise), PreCheck (healthcare), Driver iQ (trucking and transportation), eVerifile (rail and contractor), Inquiries Screening (government), IntelliCorp (small and mid-market) and CARCO (insurance risk mitigation). Cisive`s solutions deliver compliant employment intelligence to employers who are highly averse to employee-related risks and operate in highly regulated industries. With Cisive, your business will not only gain a background screening provider, but a true partnership: a company that stands by our work, protects our clients, and provides the consultation and guidance world-class organizations seek.
Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.